Basic Information
| Drug ID | DDPD00281 |
|
| Drug Name | Lidocaine | |
| Molecular Weight | 234.3373 | |
| Molecular Formula | C14H22N2O | |
| CAS Number | 137-58-6 | |
| SMILES | CCN(CC)CC(=O)NC1=C(C)C=CC=C1C | |
| External Links | ||
| DRUGBANK | DB00281 | |
| T3DB | T3D2735 | |
| PubChem Compound | 3676 | |
| PDR | 1686 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Caco-2 Permeability | -4.21 | - | -4.21 | - | ADME Research, USCD |
| Log P | 2.44 | - | 2.44 | - | AVDEEF,A (1997) |
| Boiling Point | 159.5 | ℃ | 159-160 | ℃ | PhysProp |
| Melting Point | 68.5 | ℃ | 68.5 | ℃ | PhysProp |
| Water Solubility | 4100.0 | mg/L | 4100 | mg/L | YALKOWSKY,SH & DANNENFELSER,RM 1992) |
| pKa | 8.01 | - | 8.01 | - | SANGSTER (1994) |
| Log S | -1.76 | - | -1.76 | - | ADME Research, USCD |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Absorption | 100.0 | % | 100.0 | % | parenteral administration; | DRUGBANK | |
| Bioavailability | 35.0 | % | 35.0 | % | PO, oral; | DRUGBANK | Bioavailability | 35.0 | % | 35±11 | % | parenteral administration; | The Pharmacological Basis of Therapeutics |
| C Max | 3500.0 | ng/ml | 2-5 | mcg/ml | The Pharmacological Basis of Therapeutics | ||
| Clearance | 38.4 | L/h | 0.64±0.18 | L/min | Average clearance; intravenous injection, IV; adults; | DRUGBANK | Clearance | 0.55 | L/h/kg | 9.2±2.4 | ml/min/kg | hydrolysis; | Neonates → ;Elderly ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;acute viral hepatitis AVH → ;Obesity ↓ ;congestive heart disease ↓ ;CPBS ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.96 | L/h/kg | 16 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.1 | L/kg | 0.7-1.5 | L/kg | the more highly perfused ↑ ; | DRUGBANK | Volume of Distribution | 1.1 | L/kg | 1.1±0.4 | L/kg | Neonates ↑ ;Elderly → ;congestive heart disease ↓ ;CPBS ↓ ;Hepatic cirrhosis, cirr ↑ ;RD, renal impairment, Renal disease，including uremia → ;Obesity → ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.8 | L/kg | 1.8 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 1.8 | h | 1.5-2 | h | elimination half-life; intravenous injection, IV; | hepatopathy，LD ↑ ; | DRUGBANK | Half-life | 3.0 | h | >3 | h | hepatopathy，LD; | DRUGBANK | Half-life | 1.8 | h | 1.8±0.4 | h | Neonates ↑ ;Hepatic cirrhosis, cirr ↑ ;Obesity ↑ ;RD, renal impairment, Renal disease，including uremia → ;CPBS → ;congestive heart disease → ; | The Pharmacological Basis of Therapeutics | Half-life | 1.6 | h | 1.6 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 459.0 | mg/kg | 459(346-773) | mg/kg | food; female rat; | DRUGBANK | Toxicity LD50 | 214.0 | mg/kg | 214(159-324) | mg/kg | fasting; female rat; | DRUGBANK | Toxicity LD50 | 459.0 | mg/kg | 459(346-773) | mg/kg | PO, oral; food; female rat; | T3DB | Toxicity LD50 | 214.0 | mg/kg | 214(159-324) | mg/kg | PO, oral; fasting; female rat; | T3DB |
| Eliminate Route | 5.0 | % | <5 | % | Urinary excretion; Unchanged drug; | DRUGBANK | Eliminate Route | 2.0 | % | 2±1 | % | Urinary excretion; Unchanged drug; | Neonates ↑ ; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 70.0 | % | ~60-80 | % | DRUGBANK | Protein Binding | 70.0 | % | 70±5 | % | Neonates ↓ ;Elderly ↑ ;Children → ;myocardial infarction ↑ ;CPBS ↑ ;RD, renal impairment, Renal disease，including uremia ↑ ;nephritic syndrome → ;Somking → ; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 1.0 | mg/kg | 1 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for neonates | 3.0 | mg/kg | 3 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for neonates | 72.0 | mg/kg/day | 50 | mcg/kg/minute | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
| Max dose for neonates | 2.0 | mg/kg | 2 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for neonates | 0.25 | mg/kg/day | 6 | mg/kg/hour | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
| Max dose for infants | 1.0 | mg/kg | 1 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for infants | 100.0 | mg | 100 | mg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for infants | 3.0 | mg/kg | 3 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for infants | 72.0 | mg/kg/day | 50 | mcg/kg/min | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
| Max dose for infants | 2.0 | mg/kg | 2 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for infants | 144.0 | mg/kg/day | 6 | mg/kg/h | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
| Max dose for children | 1.0 | mg/kg | 1 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for children | 100.0 | mg | 100 | mg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for children | 3.0 | mg/kg | 3 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for children | 72.0 | mg/kg/day | 50 | mcg/kg/minute | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
| Max dose for children | 2.0 | mg/kg | 2 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for children | 144.0 | mg/kg/day | 6 | mg/kg/hour | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
| Max dose for adolescents | 100.0 | mg/dose | 100 | mg/dose | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for adolescents | 300.0 | mg | 300 | mg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for adolescents | 1.5 | mg/kg/dose | 1.5 | mg/kg/dose | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for adolescents | 3.0 | mg/kg | 3 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for adolescents | 5760.0 | mg/day | 4 | mg/minute | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
| Max dose for adolescents | 72.0 | mg/kg/day | 50 | mcg/kg/minute | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
| Max dose for geriatric | 100.0 | mg/dose | 100 | mg/dose | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for geriatric | 300.0 | mg | 300 | mg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for geriatric | 1.5 | mg/kg/dose | 1.5 | mg/kg/dose | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for geriatric | 3.0 | mg/kg | 3 | mg/kg | intravenous injection, IV | Lidocaine Cream | lidocaine | PDR |
| Max dose for geriatric | 0.00277777777777778 | mg/day | 4 | mg/minute | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
| Max dose for geriatric | 72.0 | mg/kg/day | 50 | mcg/kg/minute | intravenous infusion, iv in drop | Lidocaine Cream | lidocaine | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1